In vitro comparison of dabigatran, unfractionated heparin, and low-molecular-weight heparin in preventing thrombus formation on mechanical heart valves

Thrombosis Research

Volumn 126, Issue 3, 2010, Pages

  Maegdefessel, Lars ^a,d   Linde, Torsten ^b   Krapiec, Franziska ^a   Hamilton, Kathrin ^b   Steinseifer, Ulrich ^b   Van Ryn, Joanne ^c   Raaz, Uwe ^a   Buerke, Michael ^a   Werdan, Karl ^a   Schlitt, Axel ^a  

^a MARTIN LUTHER UNIVERSITY HALLE WITTENBERG   (Germany)

^b RWTH AACHEN UNIVERSITY   (Germany)

^c BOEHRINGER INGELHEIM PHARMA GMBH AND CO KG   (Germany)

^d STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Anticoagulation; Dabigatran; Heparins; Mechanical heart valve; Thrombosis

Indexed keywords

DABIGATRAN ETEXILATE; HEPARIN; LOW MOLECULAR WEIGHT HEPARIN;

ANTICOAGULANT THERAPY; ANTICOAGULATION; ARTICLE; BLOOD CLOTTING; BLOOD CLOTTING TIME; BLOOD SAMPLING; CIRCULATION; CONTROLLED STUDY; DRUG EFFICACY; ELECTRON MICROSCOPY; HEART RATE; HEART VALVE PROSTHESIS; HUMAN; IN VITRO STUDY; MALE; NORMAL HUMAN; PRIORITY JOURNAL; PROSTHETIC VALVE THROMBOSIS; THROMBOSIS PREVENTION; THROMBUS;

ADMINISTRATION, ORAL; ANTICOAGULANTS; BENZIMIDAZOLES; BLOOD COAGULATION; FIBRINOLYTIC AGENTS; HEART VALVE PROSTHESIS; HEPARIN; HEPARIN, LOW-MOLECULAR-WEIGHT; HUMANS; MALE; PROSTHESIS DESIGN; PYRIDINES; THROMBOSIS; TIME FACTORS;

EID: 77956264209     PISSN: 00493848     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.thromres.2010.06.011     Document Type: Article

References (32)

1. S.C. Cannegieter, M. Torn, and F.R. Rosendaal Oral anticoagulant treatment in patients with mechanical heart valves: how to reduce the risk of thromboembolic and bleeding complications J Intern Med 245 1999 369 374
2. G. Palareti, J. Hirsh, C. Legnani, C. Manotti, A. D'Angelo, and V. Pengo Oral anticoagulation treatment in the elderly: a nested, prospective, case-control study Arch Intern Med 160 2000 470 478
3. American College of Cardiology/American Heart Association Task Force on Practice Guidelines; Society of Cardiovascular Anesthesiologists; Society for Cardiovascular Angiography and Interventions; Society of Thoracic Surgeons R.O. Bonow, B.A. Carabello, C. Kanu, A.C. de Leon Jr., and D.P. Faxon ACC/AHA guidelines for the management of patients with valvular heart disease. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (writing committee to revise the 1998 Guidelines for the Management of Patients With Valvular Heart Disease Circulation 114 2006 84-231
4. A. Vahanian, H. Baumgartner, J. Bax, E. Butchart, R. Dion, and G. Filippatos Task Force on the Management of Valvular Hearth Disease of the European Society of Cardiology; ESC Committee for Practice Guidelines. Guidelines on the management of valvular heart disease Eur Heart J 28 2007 230 268
5. J. Hirsh Heparin N Engl J Med 324 1987 1565 1574
6. R.D. Hull, G.E. Raskob, R.F. Brant, G.F. Pineo, G. Elliott, and P.D. Stein Low-molecular-weight heparin vs heparin in the treatment of patients with pulmonary embolism. American-Canadian Thrombosis Study Group Arch Intern Med 160 2000 229 236
7. J. Hirsh, G. Guyatt, G.W. Albers, R. Harrington, and H.J. Schünemann American College of Chest Physician. Antithrombotic and thrombolytic therapy: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition) Chest 133 2008 110 112
8. J. Harenberg, and M. Wehling Current and future prospects for anticoagulant therapy: inhibitors of factor Xa and factor IIa Semin Thromb Hemost 34 2008 39 57
9. B.I. Eriksson, H. Smith, U. Yasothan, and P. Kirkpatrick Dabigatran etexilate Nat Rev Drug Discov 7 2008 557 558
10. J.E. Eikelboom, and J.I. Weitz Dabigatran etexilate for prevention of venous thromboembolism Thromb Haemost 101 2009 2 4
11. O.E. Dahl Dabigatran etexilate: A new oral thrombin inhibitor Therapy 5 2008 1 11
12. B.I. Eriksson, O.E. Dahl, N. Rosencher, A.A. Kurth, C.N. van Dijk, and S.P. Frostick RE-MODEL Study Group. Oral dabigatran etexilate vs. subcutaneous enoxaparin for the prevention of venous thromboembolism after total knee replacement: the RE-MODEL randomized trial J Thromb Haemost 5 2007 2178 2185
13. B.I. Eriksson, O.E. Dahl, N. Rosencher, A.A. Kurth, and C.N. van Dijk RE-NOVATE Study Group. Dabigatran etexilate versus enoxaparin for prevention of venous thromboembolism after total hip replacement: a randomised, double-blind, non-inferiority trial Lancet 370 2007 949 956
14. J.S. Ginsberg, B.L. Davidson, P.C. Comp, C.W. Francis, R.J. Friedman, and M.H. Huo RE-MOBILIZE Writing Committee. Oral thrombin inhibitor dabigatran etexilate vs North American enoxaparin regimen for prevention of venous thromboembolism after knee arthroplasty surgery J Arthroplasty 24 2009 1 9
15. B.J. Bellhouse, and C. Talbot The fluid mechanics of the aortic valve J Fluid Mech 35 1969 721 735
16. H. Reul, M. Vahlbruch, and S. Effert The Geometry of the Aortic Root in Health, at Valve Disease and after Valve Replacement J Biomech 23 1990 181 189
17. H. Reul, and N. Talukter Heart valve mechanics. Quantitative Cardiovascular Studies N.H.C. Hwang, 1979 University Park Press Baltimore 527 564
18. P.Y. Huang, and J.D. Hellums Aggregation and Disaggregation Kinetics of Human Blood Platelets: Part II. Shear-induced Platelet Aggregation Biophys J 65 1993 344 353
19. M. Felfernig, A. Blaicher, S.C. Kettner, D. Felfernig, S. Acimovic, and S.A. Kozek-Langenecker Effects of temperature of partial thomboplastin time in heparinised plasma in vitro Eur J Anesthesiol 18 2001 467 470
20. L. Maegdefessel, M. Buerke, S. Schubert, I. Reindl, T. Michel, and B. Hauroeder Comparison of bivalirudin, enoxaparin, and unfractionated heparin in preventing cardiac catheter thrombosis. Results of an in-vitro study Thromb Haemost 100 2008 693 698
21. A. Schlitt, K. Hamilton, L. Maegdefessel, M. Dahm, C. Theis, and M. Eichler Comparison of fondaparinux, low molecular-weight heparin and unfractionated heparin in preventing thrombus formation on mechanical heart valves: results of an in-vitro study J Heart Valve Dis 15 2006 809 814
22. W. Wienen, J.M. Stassen, H. Priepke, U.J. Ries, and N. Hauel In-vitro profile and ex-vivo anticoagulant activity of the direct thrombin inhibitor dabigatran and its orally active prodrug, dabigatran etexilate Thromb Haemost 98 2007 155 162
23. L.P. Dasi, H.A. Simon, P. Sucosky, and A.P. Yoganathan Fluid mechanics of artificial heart valves Clin Exp Pharmacol Physiol 36 2009 225 237
24. P. Zhang, J.H. Yeo, P. Qian, and N.H. Hwang Shear stress investigation across mechanical heart valve ASAIO J 53 2007 530 536
25. C.J. Smith, J.N. Vournakis, M. Demcheva, and T.H. Fischer Differential effect of materials for surface hemostasis on red blood cell morphology Microsc Res Tech 71 2008 721 729
26. J.W. Eikelboom, and J.I. Weitz A Replacement for Warfarin: The Search Continues Circulation 116 2007 131 133
27. M.D. Ezekowitz Anticoagulation Interruptus: Not Without Risk Circulation 110 2004 1518 1519
28. A.G. Turpie The top 4 advances in antithrombotic care in the last year Thromb Res S1 2008 S2 S6
29. A.C. Spyropoulos Brave new world: the current and future use of novel anticoagulants Thromb Res S1 2008 S29 S35
30. L. Maegdefessel, T. Linde, T. Michel, K. Hamilton, U. Steinseifer, and I. Friedrich Argatroban and bivalirudin compared to unfractionated heparin in preventing thrombus formation on mechanical heart valves, results of an in vitro study Thromb Haemost 101 2009 1163 1169
31. S.J. Connolly, M.D. Ezekowitz, S. Yusuf, J. Eikelboom, J. Oldgren, and A. Parekh The RE-LY Steering Committee and Investigators. Dabigatran versus Warfarin in Patients with Atrial Fibrillation N Engl J Med 361 2009 1139 1151
32. P. Herijgers, and P. Verhamme Improving the quality of anticoagulant therapy in patients with mechanical heart valves: what are we waiting for? Eur Heart J 28 2007 2424 2426